The protective role of resveratrol against arsenic trioxide-induced cardiotoxicity

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Zhang, Weiqian ^a   Guo, Changming ^b   Gao, Ruifeng ^b   Ge, Ming ^a   Zhu, Yanzhu ^c   Zhang, Zhigang ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

^c INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATINE KINASE MB; CYCLIC AMP; GLUTATHIONE; HEME OXYGENASE 1; LACTATE DEHYDROGENASE; NITRIC OXIDE; PROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CALCIUM CELL LEVEL; CARDIOMYOPATHY; CARDIOTOXICITY; COMPARATIVE STUDY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; DRUG EXPOSURE; GENE EXPRESSION; HEART PROTECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PRISON; RAT;

EID: 84890056674     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/407839     Document Type: Article

References (37)

1. Chang Y.S., Lu K.H., Lee H.J., Huang M.L., Lai S.C., Ho Y.L., Chi C.W., Synergistic apoptosis-inducing antileukemic effects of arsenic trioxide and mucuna macrocarpa stem extract in human leukemic cells via a reactive oxygen species-dependent mechanism. Evidence-Based Complementary and Alternative Medicine 2012 2012 14 2-s2.0-80053526158 10.1155/2012/921430 921430
2. Ohnishi K., Yoshida H., Shigeno K., Nakamura S., Fujisawa S., Naito K., Shinjo K., Fujita Y., Matsui H., Takeshita A., Sugiyama S., Satoh H., Terada H., Ohno R., Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Annals of Internal Medicine 2000 133 11 881 885 2-s2.0-0034610263
3. Soignet B. S. L., Frankel S. R., Douer D., Tallman M. S., Kantarjian H., Calleja E., United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology 2001 19 18 3852 3860 2-s2.0-0035884639 (Pubitemid 32880064)
4. Westervelt P., Brown R. A., Adkins D. R., Khoury H., Curtin P., Hurd D., Luger S. M., Ma M. K., Ley T. J., DiPersio J. F., Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001 98 2 266 271 2-s2.0-0035880237 10.1182/blood.V98.2.266
5. Ficker E., Kuryshev Y. A., Dennis A. T., Obejero-Paz C., Wang L., Hawryluk P., Wible B. A., Brown A. M., Mechanisms of arsenic-induced prolongation of cardiac repolarization. Molecular Pharmacology 2004 66 1 33 44 2-s2.0-3042528658 10.1124/mol.66.1.33 (Pubitemid 38822085)
6. Hirano S., Cui X., Li S., Kanno S., Kobayashi Y., Hayakawa T., Shraim A., Difference in uptake and toxicity of trivalent and pentavalent inorganic arsenic in rat heart microvessel endothelial cells. Archives of Toxicology 2003 77 6 305 312 2-s2.0-0038346303 (Pubitemid 36819260)
7. Hwang J.T., Kwon D. Y., Park O. J., Kim M. S., Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes and Nutrition 2008 2 4 323 326 2-s2.0-41349084391 10.1007/s12263-007-0069-7 (Pubitemid 351447706)
8. Manna P., Sinha M., Sil P. C., Arsenic-induced oxidative myocardial injury: protective role of arjunolic acid. Archives of Toxicology 2008 82 3 137 149 2-s2.0-41849147561 10.1007/s00204-007-0272-8
9. Dudka J., Gieroba R., Korga A., Burdan F., Matysiak W., Jodlowska Jedrych B., Mandziuk S., Korobowicz E., Murias M., Different effects of resveratrol on dose-related Doxorubicin-induced heart and liver toxicity. Evidence-Based Complementary and Alternative Medicine 2012 2012 10 606183 10.1155/2012/606183
10. Das S., Das D. K., Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Patents on Cardiovascular Drug Discovery 2007 2 2 133 138 2-s2.0-34250756115 10.2174/157489007780832560 (Pubitemid 46957321)
11. Sulaiman M., Matta M. J., Sunderesan N. R., Gupta M. P., Periasamy M., Gupta M., Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. American Journal of Physiology: Heart and Circulatory Physiology 2010 298 3 H833 H843 2-s2.0-77749254621 10.1152/ajpheart.00418.2009
12. Baur J. A., Pearson K. J., Price N. L., Jamieson H. A., Lerin C., Kalra A., Prabhu V. V., Allard J. S., Lopez Lluch G., Lewis K., Pistell P. J., Poosala S., Becker K. G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K. W., Spencer R. G., Lakatta E. G., Le Couteur D., Shaw R. J., Navas P., Puigserver P., Ingram D. K., De Cabo R., Sinclair D. A., Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006 444 7117 337 342 2-s2.0-33751072349 10.1038/nature05354 (Pubitemid 44764104)
13. Park S.J., Ahmad F., Philp A., Baar K., Williams T., Luo H., Ke H., Rehmann H., Taussig R., Brown A. L., Kim M. K., Beaven M. A., Burgin A. B., Manganiello V., Chung J. H., Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012 148 3 421 433 2-s2.0-84856693544 10.1016/j.cell.2012.01.017
14. Tennen R. I., Michishita Kioi E., Chua K. F., Finding a target for resveratrol. Cell 2012 148 3 387 389 2-s2.0-84856731505 10.1016/j.cell.2012.01. 032
15. Zhao X.Y., Li G.Y., Liu Y., Chai L.M., Chen J.X., Zhang Y., Du Z.M., Lu Y.J., Yang B.F., Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo. British Journal of Pharmacology 2008 154 1 105 113 2-s2.0-42949148136 10.1038/bjp.2008.81 (Pubitemid 351620407)
16. Maxwell D. P., Wang Y., McIntosh L., The alternative oxidase lowers mitochondrial reactive oxygen production in plant cells. Proceedings of the National Academy of Sciences of the United States of America 1999 96 14 8271 8276 2-s2.0-0033529335 10.1073/pnas.96.14.8271 (Pubitemid 29328444)
17. Lakritz J., Plopper C. G., Buckpitt A. R., Validated high-performance liquid chromatography-electrochemical method for determination of glutathione and glutathione disulfide in small tissue samples. Analytical Biochemistry 1997 247 1 63 68 2-s2.0-0031553958 10.1006/abio.1997.2032 (Pubitemid 27161494)
18. Csanaky I., Gregus Z., Effect of selenite on the disposition of arsenate and arsenite in rats. Toxicology 2003 186 1-2 33 50 2-s2.0-0037447611 10.1016/S0300-483X(02)00604-2 (Pubitemid 36246618)
19. 2+ indicators with greatly improved fluorescence properties. Tanpakushitsu Kakusan Koso 2007 52 13 1758 1759 2-s2.0-38449121765
20. Shi X., Zhou B., The role of Nrf2 and MAPK pathways in PFOS-induced oxidative stress in zebrafish embryos. Toxicological Sciences 2010 115 2 391 400 2-s2.0-77954080340 10.1093/toxsci/kfq066
21. Aposhian H. V., Aposhian M. M., Arsenic toxicology: five questions. Chemical Research in Toxicology 2006 19 1 1 15 2-s2.0-31844439261 10.1021/tx050106d (Pubitemid 43185456)
22. Oudit G. Y., Trivieri M. G., Khaper N., Husain T., Wilson G. J., Liu P., Sole M. J., Backx P. H., Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation 2004 109 15 1877 1885 2-s2.0-1942534543 10.1161/01.CIR.0000124229.40424.80 (Pubitemid 38509123)
23. Yang Y., Chan S. W., Hu M., Walden R., Tomlinson B., Effects of some common food constituents on cardiovascular disease. ISRN Cardiology 2011 2011 16 397136 10.5402/2011/397136
24. Bassenge E., Sommer O., Schwemmer M., Bünger R., Antioxidant pyruvate inhibits cardiac formation of reactive oxygen species through changes in redox state. American Journal of Physiology: Heart and Circulatory Physiology 2000 279 5 H2431 H2438 2-s2.0-0033672337
25. Hou D.X., Korenori Y., Tanigawa S., Yamada Kato T., Nagai M., He X., He J., Dynamics of Nrf2 and Keap1 in ARE-mediated NQO1 expression by wasabi 6-(methylsulfinyl)hexyl isothiocyanate. Journal of Agricultural and Food Chemistry 2011 59 22 11975 11982 2-s2.0-81255138105 10.1021/jf2032439
26. Baur J. A., Sinclair D. A., Therapeutic potential of resveratrol: the in vivo evidence. Nature Reviews Drug Discovery 2006 5 6 493 506 2-s2.0-33745962138 10.1038/nrd2060 (Pubitemid 44136961)
27. El Hamamsy I., Stevens L.M., Carrier M., Pellerin M., Bouchard D., Demers P., Cartier R., Page P., Perrault L. P., Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. Journal of Thoracic and Cardiovascular Surgery 2007 133 1 7 12 2-s2.0-33845783844 10.1016/j.jtcvs.2006.05.070 (Pubitemid 46014198)
28. Kinlay S., Behrendt D., Fang J. C., Delagrange D., Morrow J., Witztum J. L., Rifai N., Selwyn A. P., Creager M. A., Ganz P., Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. Journal of the American College of Cardiology 2004 43 4 629 634 2-s2.0-10744222579 10.1016/j.jacc.2003.08.051 (Pubitemid 38229536)
29. Joseph M., Tze chen H., Wang Z. R., Cardioprotection by resveratrol: a review of effects/targets in cultured cells and animal tissues. American Journal of Cardiovascular Disease 2011 1 38 47
30. Zhang W., Xue J., Ge M., Yu M., Liu L., Zhang Z., Resveratrol attenuates hepatotoxicity of rats exposed to arsenic trioxide. Food and Chemical Toxicology 2013 51 87 92 10.1016/j.fct.2012.09.023
31. Haskó G., Pacher P., Endothelial Nrf2 activation: a new target for resveratrol? American Journal of Physiology: Heart and Circulatory Physiology 2010 299 1 H10 H12 2-s2.0-77953734595 10.1152/ajpheart.00436.2010
32. Shaw R. M., Rudy Y., Ionic mechanisms of propagation in cardiac tissue: roles of the sodium and L-type calcium currents during reduced excitability and decreased gap junction coupling. Circulation Research 1997 81 5 727 741 2-s2.0-0030665763 (Pubitemid 27467208)
33. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 Cell 2006 127 6 1109 1122 2-s2.0-33845399894 10.1016/j.cell.2006.11.013 (Pubitemid 44894520)
34. Orrenius S., Kaminskyy V. O., Zhivotovsky B., Autophagy in toxicology: cause or consequence? The Annual Review of Pharmacology and Toxicology 2013 53 275 97 10.1146/annurev-pharmtox-011112-140210
35. Sumi D., Sasaki T., Miyataka H., Himeno S., Rat H9c2 cardiac myocytes are sensitive to arsenite due to a modest activation of transcription factor Nrf2. Archives of Toxicology 2011 85 12 1509 1516 2-s2.0-82355182875 10.1007/s00204-011-0700-7
36. Athar M., Back J. H., Tang X., Kim K. H., Kopelovich L., Bickers D. R., Kim A. L., Resveratrol: a review of preclinical studies for human cancer prevention. Toxicology and Applied Pharmacology 2007 224 3 274 283 2-s2.0-34547882115 10.1016/j.taap.2006.12.025 (Pubitemid 47575677)
37. Matés J. M., Segura J. A., Alonso F. J., Márquez J., Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Archives of Toxicology 2008 82 5 273 299 2-s2.0-43749092334 10.1007/s00204-008-0304-z